Global After a challenging 2020, and with more hurdles in sight, Bayer has been on an investment spree with a USD 2 billion acquisition of a San Diego-based biotech and manufacturing sites in Latin America and Norway. Bayer had a challenging year in 2020. While the German giant argued in…
Global PharmaBoardroom has spoken to leaders from several important global patient advocacy organisations in 2021 who shared their concerns on crucial global healthcare issues. These range from the greater levels of pharma industry investment needed in childhood cancers; the myriad of patient explanation and expectation management needed around CAR-T therapies; how…
USA Claire Saxton and Lauren Kriegel of Cancer Support Community, the largest professionally led non-profit network of cancer support worldwide, discuss how cancer patient and caregiver perspectives need to be better integrated into the treatment process. This is an especially prescient issue for next-generation cell and gene therapies such as CAR-T…
Global Carlo Toniatti, chief scientific officer of IRBM, gives his insights into how the increased participation of early-stage ventures in the drug R&D process and the plethora of new research approaches that are recalibrating the role of CROs such as IRBM. An experienced oncologist, Toniatti also weighs in on the key…
Global Lorna Warwick is CEO of the Lymphoma Coalition, a worldwide network of patient groups with a full or partial focus on providing support to patients with lymphoma. In this wide-ranging interview, Warwick highlights the progress made in lymphoma treatment in recent years and the work still to be done to…
Global Shawview Consulting’s Brendan Shaw examines the WHO’s recently released updated Essential Medicines List. Shaw highlights some of the key trends and new inclusions in the List, why pricing and transparency are hotter topics than ever, and how pharma can incorporate this important document and its implications into their strategies for…
Global Paula Barbosa, head of influenza policy and advocacy at the IFPMA and board member of the #TogetherAgainstFlu campaign, looks ahead to what could be a devastating 2021/22 flu season, with natural immunity among vulnerable populations down following the pandemic induced lockdowns and preventive measures of last year. Barbosa lays out…
Denmark Speaking exclusively to PharmaBoardroom, Lundbeck’s global CEO Deborah Dunsire describes the progress in the strategy she put in place to “revitalise and refresh” the Danish firm’s pipeline upon taking the role three years ago. Following two recent acquisitions, Lundbeck now has a much broader focus across neuroscience including areas for…
Global The global push to vaccinate populations against COVID-19 has played out differently in different geographies, with a yawning gap still existing between vaccination rates in developed and developing economies and vaccine hesitancy and scepticism rife in certain countries. Here, three country managers from Pfizer – which is aiming to manufacture…
Global Pharma industry leaders have called for rich nations to stop stockpiling excess COVID-19 vaccine doses and stated that there will be enough production by the end of the year to cover the entire global population. The head of Pfizer, J&J, and industry association the IFPMA also hope that this surge…
Global Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, highlights the achievements of the company’s Rare Humanitarian Program over the last 30 years, bringing treatments to patients in developing countries with lysomal storage disorders who would otherwise not have access. Sibold outlines the persistent obstacles facing people with rare…
See our Cookie Privacy Policy Here
